AMOYTOP(SH:688278) Ge Long Hui A P P·2025-11-17 12:36Core Viewpoint - The company is committed to supporting children with growth hormone deficiency through a charitable initiative, addressing both health and economic challenges faced by affected families [1] Group 1: Company Initiatives - The company has developed a national class 1 new drug, Yipeisheng (怡培生长激素注射液), for treating growth hormone deficiency in children aged 3 and above [1] - The company has decided to donate up to 40,000 doses of Yipeisheng and up to 661,600 RMB in cash to the Beijing Hongxin Xiangtong Charity Foundation to support the "Yilu Xiangban" patient assistance project [1] Group 2: Industry Context - Growth hormone deficiency in children can lead to various issues, including reduced height, lower quality of life, and potential behavioral, cognitive, and psychological disorders [1] - The initiative aligns with the "Healthy China 2030" planning outline, aiming to provide continuous and standardized treatment for more children in need [1]